Status:
COMPLETED
Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery
Lead Sponsor:
Peking University First Hospital
Conditions:
Overall Survival
Eligibility:
All Genders
60+ years
Phase:
PHASE4
Brief Summary
This is a 3-year follow-up of patients enrolled in a previous randomized controlled trial which showed that intraoperative dexmedetomidine reduced delirium in elderly patients after major non-cardiac ...
Detailed Description
Dexmedetomidine is a highly selective α-2-receptor agonist with sedative, analgesic and anxiolytic effects. When used as an supplement during general anaesthesia, it reduces the consumption of the ana...
Eligibility Criteria
Inclusion
- Elderly patients (age ≥60 years);
- Scheduled to undergo elective major non-cardiac surgery with expected duration ≥2 hours under general anaesthesia.
Exclusion
- Do not provide written informed consent;
- Previous history of schizophrenia, epilepsy or Parkinson's disease;
- Visual, hearing, language or other barriers which impede communication and preoperative delirium assessment;
- History of traumatic brain injury;
- Severe bradycardia (heart rate \<40 beats per minutes), sick sinus syndrome, or atrioventricular block of degree 2 or above without pacemaker;
- Severe hepatic dysfunction (Child-Pugh grade C);
- Renal failure (requirement of renal replacement therapy);
- Neurosurgery.
Key Trial Info
Start Date :
October 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
619 Patients enrolled
Trial Details
Trial ID
NCT04111926
Start Date
October 7 2019
End Date
April 1 2021
Last Update
April 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034